ACOI 2017 Nephrology Cases

62 yo male who was dxed with metastatic NSCLC 6 months ago and was treated with conventional therapy and XRT. Because of disease progression, he was started on ipilimumab (Yervoy) for which he had received his 2nd cycle 10 days ago PMH HTN Meds amlodipine 10 daily and ASA 81 mg

72 hours prior to admission he started to have increased weakness with orthostasis. He has poor oral intake. He was taken to the hospital by EMS after an episode of syncope

On arrival he was lethargic and his BP was 65/ HR 120 Nothing else on exam except for decreased volume

He was immediately given 30 ml/kg and labs were drawn

Labs: BUN 70/Cre 8 Na 126/K 6.4/Cl 100/HCO3 8 Glucose 45 Ca, PO4, Mg OK. CK normal CBC WBC 18 Nl diff; H/H 14/40; PLT 420 UA 10 RBCs; 10-20 WBC; UAC 210 UPC 700 +granular casts ECG, CXR, Chest CT, US kidneys/bladder all negative


After the bolus his BP was 8o/ and another 3o ml/kg of NSS given. He was placed on an infusion supplemented with Na acetate (Yes we had no NaHCO3)

- A cortisol was drawn and he was given hydrocortisone 100 IV q8
- Hemodynamically he was stabilized but he made < 500 ml urine over the 1st 24hrs


On day 2, he felt better but was still making little urine. MAP > 65 without pressors Labs: BUN 90/Cre 9.5/Na 128/K 6/Cl100/HCO3 9 Cortisol 3. ACTH, TSH and prolactin sent

Because of oliguria and refractory acidosis, hemodialysis was started via IJ catheter


He had persistent oliguria and tolerated dialysis TSH, ACTH and prolactin levels all low – confirming panhypopituitarism and hydrocortisone was tapered 1 week into his course he was still oliguric. Repeat UA – 10-15 RBCs, 20 WBCs, UAC 250, UPC 725, still with granular casts Renal biopsy performed



Interstitial nephritis and ATN



IgG no specific staining



No immune complex deposits seen.

Checkpoint Inhibitors

CTLA-4 Inhibitor Ipilimumab (Yervoy) PD-1 Inhibitor Pembrolizumab (Keytruda) Nivolumab (Opdivo) PD-L1` Inhibitor Durvalumab (Imfinzi) Atezolizumab (Tecentriq)

CPI Immune related Adverse Reactions

Skin – rash CV – myocarditis Endocrine – thyroiditis, pancreatitis, panhypopituitarism Neurologic – myasthenia gravis Lungs –pneumonitis GI – colitis, hepatitis Kidney – nephritis, hypoNa

CPI Kidney Pathophysiology

Classic AIN – CPI as hapten Unmasking of tolerance to drug leading to AIN Immune mediated adverse reaction (autoimmunity)

Wanchoo et al. Am J Nephrol 2017;45:160-169 (DOI:10.1159/000455014)




Fig. 1. CTLA-4 and PD-1 signaling networks at homeostasis. Integration of both positive and negative costimulatory signals during and after the initial T-cell activation will determine the fate and intensity of the alloimmune response. The first step in antigen (Ag) recognition is the binding of the antigen to major histocompatibility complex (MHC) molecules on the antigen presenting cell (APC) and creating a complex with the T cell receptor (TCR) located on the T cell. This is followed by the interaction of the CD28 molecule with B7 (CD 80/86) initiating a co-stimulatory signal leading to further T-cell stimulation (this is in addition to other co-stimulatory molecules not depicted here). As a negative feedback process to prevent overstimulation, T-cell activation leads to the upregulation of the CTLA-4 molecule, which competes with the B7-CD28 ligand and in turn leads to T-cell arrest, thus providing brakes to the immune system. Similarly, binding of the PD-1 molecule with PD-L1 and PD-L2 leads to an inhibitory signal with decreased effector T-cell function, suppressing immune surveillance and permitting neoplastic growth. It has to be noted that the majority of data supports the role of increased PD-L1 expression in human tumors and serves as the biomarker to consider PD-1 inhibitors for treatment. The role of PD-L2 in specific tumor immunology in humans is not well defined.

Wanchoo et al. Am J Nephrol 2017;45:160-169 (DOI:10.1159/000455014)




Fig. 2. Ipilimumab or CTLA-4 antagonist binds to the CTLA-4 molecule and prevents it from binding to B7, leading to the sustained activation of the T cell (lifting the foot off the brakes). PD-1 inhibitors bind to the PD-1 molecule preventing its interaction with PD-L1/L2, thus leading to continued T-cell stimulation (pressing on the accelerator). It has to be noted that the majority of data supports the role of increased PD-L1 expression in human tumors and serves as the biomarker to consider PD-1 inhibitors for treatment. The role of PD-L2 in specific tumor immunology in humans is not well defined.

Wanchoo et al. Am J Nephrol 2017;45:160-169 (DOI:10.1159/000455014)

Drug name	Renal impairment*	Hypokalemia	Hyponatremia	Hypomagnesemia	Hyperkalemia	Hypophosphatemia	Hypernatremia	Grand total
Ipilimumab	220	64	159	8	19	13	0	483
Nivolumab	20	5	14	2	4	1	0	44
Pembrolizumab	16	3	19	0	1	0	0	39

The numbers in the cell represent the total number of events of each category for the 3 immune check point inhibitors.

* Renal impairment comprises proteinuria, renal failure acute, acute kidney injury, elevated creatinine, hypercreatinemia, and nephritis.

** Bolded numbers represents most common reported reaction.

*** The search terms used for the FAERS database were "renal impairment, proteinuria, renal failure acute, acute kidney injury, elevated creatinine, hypercreatinemia nephritis, hyponatremia, hypokalemia, hypernatremia, hyperkalemia, hypophosphatemia, hypocalcemia, hypercalcemia, hypomagnesemia, and hypertension." There are important limitations with the FAERS database. The events are reported by providers and/or patients and there could be a reporting bias. In addition, not all demographic and comorbidity information is available to help identify if other nephrotoxic risk factors are present.

Table 1. Common reported renal adverse events to the FDA adverse reporting database (FAERS) from 2011 3rd quarter to 1st quarter of 2015

Wanchoo et al. Am J Nephrol 2017;45:160-169 (DOI:10.1159/000455014)

Agents	CTLA-4 antagonists (ipilimumab)	PD-1 inhibitors (nivolumab and pembrolizumab)
Mechanistic differences	 Limits T-cell response early in the immune response in lymphoid tissues Expressed by T cells CTLA-4 ligands expressed by antigen-presenting cells 	 Limits T-cell response later in the immune response, primarily in peripheral tissues Expressed by T cells and other immune cells PD-1 ligands expressed by antigen-presenting cells and other immune cells and can be inducibly expressed in non-immune cells including tumor cells
Cancer	Metastatic melanoma**, lung cancer*, renal cell cancer*, prostate cancer*, cervical cancer*, colorectal cancer*, pancreatic cancer*, ovarian cancer*, urothelial cancer*	Metastatic melanoma**, non small cell lung cancer **, gastric cancer*, head and neck cancer*, urothelial cancer*, colorectal cancer*, gliobastoma*, pancreatic cancer*, hematologic malignancies*
Onset of AIN	AIN appears 6–12 weeks after initiation of therapy, with longest duration being 26 weeks. Late onset associated with more severe AKI requiring renal replacement therapy	AIN appears 3–12 months after initiation of therapy
Glomerular findings	Podocytopathy (membranous nephropathy and minimal change disease) and thrombotic microangiopathy reported	No cases of podocytopathy reported
Gender	No gender preferences	No gender preferences
Electrolyte disorders	Hyponatremia cases related to hypophysitis (secondary adrenal insufficiency)	Hyponatremia is rare
Transplant	In renal transplant patients, 2 cases reported no rejection when given as a solo agent	When given- patients had rejection especially following use with CTLA-4 inhibitors (4 cases reported), likely due to loss of tolerance
AIN, acute	interstitial nephritis.	

AIN, acute interstitial nephritis.

** FDA approved, * in phase 2 or 3 clinical trials.

Table 2. Renal effects of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antagonists and the programmed death-1 (PD-1) inhibitors

Pt	Urine sediment ^a	Proteinuria (dipstick/UPCR)	Day of AKI ^b	Days since last dose of CPI	Eos	HTN ^c	Oliguria ^d	Kidney size (cm)	Peak SCr (mg/dl)	Requirement for RRT	IRAEs
1	5–10 WBCs ^e 2 RBCs	1+/0.6	54	54	No	No	No	R 12.8 L 13.8	6.2	No	Hypophysitis
2	2–3 WBCs 3–5 RBCs	Trace/NA	91	49	No	No	No	R 12.2 L 13.2	4.1	No	Thyroiditis; ileitis
3	5–10 WBCs 0 RBCs 0–2 WBC casts	Trace/NA	69	14	No	No	No	R 11.6 L 12.6	9.7	3 HD treatments starting on day 130	Hepatitis
4	16–34 WBCs	NA/NA	70	28	NA	No	No	R 13.0 L 13.0	3.6	No	None
5	5 WBCs ^e 1 RBC	Neg/0.26	245	63	No	No	No	R 13.2 L 13.0	2.9	No	Hypophysitis; thyroiditis
6	0 WBC 0 RBC	Neg/0.74	183	36	No	Yes	Yes	R 10.9 L 13.5	11.7	HD-dependent starting on day 183	Hypophysitis; ^f colitis
7	0 WBC ^e 0 RBC	Neg/NA	224	14	No	No	No	R 11.8 L 12.2	3.8	No	Sicca syndrome with sialadenitis on lip biopsy; colitis
8	6–9 WBCs 0–3 RBCs	1+/0.98	154	7	No	No	Yes	R 12.8 L 11.8	5.6	HD-dependent starting on day 210	None
9	9 WBCs ^e 8 RBCs WBC casts	2+/0.12	42	21	No	Yes	No	R 12.4 L 13.0	7.3	No	Rash; colitis
10	3 WBCs ^e 3 RBCs WBC casts	1+/0.73	120	57	No	No	No	R 8.0 L 10.0	2.9	No	None
11	50–100 WBCs 0–2 RBCs	1+/0.18	60	18	14.7%	No	No	R 10.2 L 10.0	4.5	No	None
12	20–50 WBCs 0-2 RBCs	1+/NA	21	21	No	No	No	NA	13.3	3 HD treatments starting on day 21	None
13	11–20 WBCs 0 RBCs	Neg/0.36	231	21	No	No	No	R 10.7 L 11.9	2.5	No	lritis; colitis
Mee IQR	dian	0.48 0.24–0.73	91 60–183	21 18–49				R 12.0, L 12.8 R 10.9–12.8 L 11.9-13.1	4.5 3.6–7.3		

Table 2 | Clinical features of CPI-induced AKI

CPI Nephropathy

Timing is variable – 1- 9 months Incidence – 10-30% ?? Severity usually severe – Stage 3 AKI More common with CTLA-4 and PD-1 combination. Associated with other IRAEs Responds to steroids May lead to transplant rejection Permanent discontinuation of PDI

He was treated with prednisone 1 mg/kg for 1 month and then tapered over the next 3 months Dialysis was stopped after 3 weeks He has not been re-challenged with CPI


75 yo woman with a > 10 year hx of DM II and HTN who is admitted for AKI (normal eGFR 6 months ago)

- 3 months of constitutional symptoms weakness, lethargy and more recently anorexia and nausea. + myoclonic jerks. + cough
- ROS negative except above
- Meds: metformin ASA and lisinopril


Labs: BUN 90/Cre 9/Na 138/K 6/Cl 110/HCO3 14 UA – + dysmorphic RBCs, few WBCs, few RTEs, no cellular casts UAC 2300 UPC 3500 US kidneys, CXR bilateral infiltrates Serologic workup ordered Placed on dialysis after no improvement for 48 hrs

Complements normal + anti MPO in high titer. All of the rest of the serologic workup including anti GBM negative


Renal biopsy performed




A big cellular crescent. PAS



A well preserved glomerulus. PAS




Interstitial inflammation, segmental glomerular necrosis (arrow). H&E




Vasculitis with fibrinoid necrosis of the arterial wall (arrows). Methylene blue basic fuchsin stained semithin sections cut from the tissue submitted for electron microscopy.

She was treated with high dose solumedrol A discussion with patient regarding options and we decided on :

Prednisone 60 with taper after 1 month IV cyclophosphamide 15 mg/kg IV q2-3 weeks Plasmapheresis 60 ml/kg for 7 exchanges DS TMP/SMX prophylaxis 3X weekly




Clinical outcomes: the treatment response beyond 4 months after biopsy is uncommon.




Taewoo Lee et al. CJASN 2014;9:905-913

Among cyclophosphamide-treated patients, the likelihood of treatment response was >14% (lowest confidence limit) even with highest chronicity index score and eGFR<10 ml/min per 1.73 m2.




Taewoo Lee et al. CJASN 2014;9:905-913

Probability of cumulative incidence of ESRD, disease-related death, or death from other cause for the entire cohort.



Taewoo Lee et al. CJASN 2014;9:905-913



Summary

Response rate even for severe renal failure txed with steroids and CYP 50% Mortality 15-20% and more likely if on dialysis If no response by 4 months < 5% responded Age, female sex, high chronicity index and eGFR < 10 predicted non-response


Demographic and Clinical Characteristics of the Patients at Trial Entry

Variable	Rituximab Group (N=33)	Control Group (N=11)
Age — yr	47 B	a (1
Median	68	67
Interquartile range	56-75	58-76
Male sex — no. (%)	17 (52)	6 (55)
Diagnosis — no. (%)		
Wegener's granulomatosis	18 (55)	4 (36)
Microscopic polyangiitis	12 (36)	4 (36)
Renal-limited vasculitis	3 (9)	3 (27)
Proteinase 3 and myeloperoxidase-ANCA binding — U/ml		
Median	53	79
Interquartile range	14-100	28-163
ANCA-positive labeling pattern — no. (%)		
Cytoplasmic	20 (61)	5 (45)
Perinuclear	13 (39)	6 (55)
Glomerular filtration rate — ml/min/1.73 m² j	-	
Median	20	12
Interquartile range	5-44	9-33
Organs involved — no.		
Median	3	2
Interquartile range	1-4	1-4
Birmingham Vasculitis Activity Score		
Median	19	18
Interquartile range	14–24	12-25
C-reactive protein — mg/dl		
Median	28	25
Interquartile range	12-87	7-87
Erythrocyte sedimentation rate — mm/hr		
Median	52	64
Interquartile range	14-82	21-106
Dialysis required at entry — no. (%)	8 (24)	1 (9)
Intravenous methylprednisolone — g		
Median	1	1
Interquartile range	1-1	1-1

* ANCA denotes antineutrophil cytoplasmic antibody.

 \uparrow The glomerular filtration rate was 0 ml per minute among patients who underwent dialysis.

Cumulative Incidence of Remission and Cumulative Proportion of Patients with a Severe Adverse Event



RITUXIVAS Summary

Response rate 76 and 82% (GFR 15-20) Death rate 16% Complication rate 40% Dialysis 9 patients – 5/9 came off dialysis

Randomized Trial of Plasma Exchange or High-Dosage Methylprednisolone as Adjunctive Therapy for Severe Renal Vasculitis


Table 1.

Baseline clinical and serologic characteristics of the patients with ANCA-associated systemic vasculitis and renal failure^a

Clinical and Laboratory Features at Entry	Intravenous Methylprednisolone $(n = 67)$	Plasma Exchange($n = 70$)	Total(<i>n</i> = 137)	P
Age (yr; median [range])	66 (27 to 81)	67 (28 to 79)	66 (27 to 81)	0.93
Female gender (n [%])	24 (36)	29 (41)	53 (38.7)	0.50
Wegener's granulomatosis/microscopic polyangiitis (n [%])	24/43 (35.8/64.2 8)	18/52 (25.7/74.3)	42/95 (30.7/69.3)	0.20
Nonoliguric/dialysis requiring (n [%])	19/48 (28.4/71.6)	23/47 (32.9/67.1)	42/95 (30.7/69.3)	0.57
PR3-ANCA (n [%])	31 (46.3)	26 (37.1)	57 (42.6)	0.35
MPO-ANCA (n [%])	31 (46.3)	40 (57.1)	71 (51.9)	
ANCA negative (n [%])	3 (4.5)	4 (5.7)	7 (5.3)	
BVAS	21 (12 to 41)	21 (12 to 39)	21 (12 to 41)	0.69
Vasculitis Damage Index (median [range])	0 (0 to 4)	0 (0 to 7)	0 (0 to 7)	0.86
Creatinine (µmol/L; median [range])	718 (498 to 1566)	754 (500 to 1669)	735 (498 to 1669)	0.96
C-reactive protein (mg/L; median [range])	108 (2 to 264)	76 (7 to 281)	93 (2 to 281)	0.23
Erythrocyte sedimentation rate (mm/h; median [range])	84 (2 to 150)	94 (20 to 140)	89 (2 to 150)	0.34


 →^a ANCA, autoantibodies to neutrophil cytoplasmic antigens; BVAS, Birmingham Vasculitis Activity Score; MPO, myeloperoxidase; PR3, proteinase 3.

Proportion of patients in each group without progression to ESRD



David R.W. Jayne et al. JASN 2007;18:2180-2188

Sequential serum creatinine (µmol/L) for those who recovered renal function (mean; 95% confidence interval [CI]).



David R.W. Jayne et al. JASN 2007;18:2180-2188

MPEX Summary

Endpoint dialysis independence 49 VS 69% NNT 5 ESRD 19 VS 43% NNT 4-5 Patient survival (73%) and complication rates (50%) were the same

Dialysis was continued via TVC She received CYP 15 mg/kg and she was discharged for outpatient pheresis 60 ml/kg for 7 TX She completed her plasmapheresis and her WBC nadir was > 5 She was given her 2nd dose of CYP 3 weeks after the 1st No signs of renal recovery thus far

- 2 weeks post her 2nd dose of CYP she developed fevers and weakness and went to ER
- CXR showed LLL infiltrate and patient admitted to ICU with qSOFA of $_{\mbox{3}}$
- She required IVF, mechanical ventilation, IV pressors and broad spectrum abx, Despite this she had refractory shock and died 36 hours into her hospitalization
- BC grew Cryptyococcus neoformans

	Study Groups					
Adverse Event	Intravenous N	/lethylprednisolone	Plasm	– Total		
	Mild/ Moderate	Severe/Life Threatening	Mild/ Moderate	Severe/Life Threatening	Total	
Leukopenia (at least 1 episode)	35	7	35	8	85	
Recurrent leukopenia (>1 episode)	13	2	11	4	30	
Infection	13	17	11	20	61	
Thrombocytopenia	2	0	3	5	10	
Allergy	4	0	6	0	10	
Cardiovascular	2	3	1	3	9	
Diabetes	3	2	2	1	8	
Gastrointestinal	0	1	3	2	6	
Bone fracture	0	2	1	2	5	
Thrombosis	1	0	1	3	5	
Hemorrhage	0	1	1	1	3	
Alopecia	0	0	2	0	2	
Vascular access complication	0	1	0	1	2	
Other	1	3	2	2	8	
Totals	74	39	79	52	244	
No.(%) of patients with ≥ 1 event	59 (87)	32 (48)	63 (91)	35 (50)	122 (89)	

Table 3. Adverse events according to type, severity (mild/moderate or severe/life threatening), and treatment group

Severe Renal Involvement in AAV

Patient with severe renal involvement have a higher mortality than rest of AAV patients likely due to disease ESRD population much higher risk population Death due to CV events on dialysis, dx complications and infection There is no degree of renal disease that treatment is no warranted